GED - a generalised syntax editor : a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Computer Science at Massey University

This thesis traces the development of a full-screen syntax-directed editor - a type of editor that operates on a program in terms of its syntactic tree structure instead of its sequential character representation. The editor is table-driven, reading as input an extended BNF syntax of the target language. It can therefore be used for any language whose syntax can be defined in EBNF. Print formatting information can be included with the syntactic definition to enable programs to be pretty-printed when they are displayed. The user is presented with a pretty-printed skeletal outline of a program with the currently selected construct highlighted and all required syntactic items provided by the editor. Any constructs with alternatives, such as "", which occurs in many languages, are initially denoted by a placeholder in the form of a non-terminal name (i.e. "") which is expanded when the user indicates which alternative is wanted. All symbols entered by the user are parsed immediately and any erroneous symbols rejected, making it impossible to create a syntactically incorrect program. The editor cannot detect semantic errors as no semantic information is available from the EBNF syntax. However the first use of all identifiers is flagged by the editor as an aid to the detection of undeclared identifiers. A "help" area at the bottom of the screen continuously displays a list of the correct next symbols and the syntactic definition of the currently selected program construct. This display, together with a multi-level "undo" command and the provision of a skeletal program by the editor, provides a way of exploring the various constructs in a programming language, while ensuring the syntactic correctness of the resultant program

1-year prospective real life monitoring of asthma control and quality of life in Italy

Objectives: The study aimed at prospectively evaluating the evolution of asthma control in Italy, to evaluate the reasons for lack of asthma control, perceived quality of life (QoL) and association with level of asthma control, the impact of pharmacological treatment, the number of exacerbations and the healthcare resource consumption.Methods: PRISMA (PRospectIve Study on asthMA control) was an observational study performed in asthmatic patients including a cross-sectional phase and a 12-month prospective phase. Asthma control was assessed with the Asthma Control Test™ (ACT) and QoL was evaluated with EuroQoL-5D questionnaire filled in and collected during 5 clinic visits together with all the other data.Results: The prospective phase included 1017 patients with uncontrolled (55.7%) or partly controlled asthma (44.3%). Out of the 739 patients evaluable after 12 months, 22.2% achieved full asthma control (ACT score = 25) and 58.7% reached a good control (ACT score: 20-24). The improvement in asthma control was associated with improved QoL and reduced hospital visits. The main reasons for lack of asthma control were comorbidities, continued exposure to irritants/triggers and poor adherence to therapy. The frequency of exacerbations was lower in patients with controlled asthma.A fixed combination therapy with an inhaled corticosteroid and a long-acting β2 agonist was reported by 77.0% of patients. A better asthma control and improved QoL were achieved with extrafine beclomethasone/formoterol compared to either budesonide/formoterol or fluticasone/salmeterol.Conclusions: An improvement in asthma control and QoL can be achieved during a 1-year monitoring in a real life setting. Extrafine beclomethasone/formoterol was associated with significant benefit in terms of asthma control and QoL compared to large-particles combinations.ClinicalTrials.gov number NCT01110460. © 2012 Terzano et al.; licensee BioMed Central Ltd